北京若生智能科技有限公司
Drug Database
IO

ior-t3 (IORt3)

✓ Approved

Center of Molecular Immunology · CD3E · 单克隆抗体

什么是 ior-t3？

ior-t3 是一种单克隆抗体，由Center of Molecular Immunology研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)。

药物档案

商品名IORt3
公司Center of Molecular Immunology
药物类别单克隆抗体, 抗体
分子靶点CD3E
给药途径Injectable (Others)
状态Approved
来源： ClinicalTrials.gov, Center of Molecular Immunology

作用机制

分子靶点

ior-t3 作用于 1 个分子靶点：

CD3ECD3 epsilon subunit of T-cell receptor complex (TCRE, CD3epsilon)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

ior-t3 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Immune system disordersSolid organ transplant rejection✓ Approved

相关研究文献

PubMedCurrent oncology (Toronto, Ont.)2026-10-26

A Remotely Delivered Exercise-Based Rehabilitation Program for Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy (EX-CIPN): A Phase I Feasibility Trial.

Antonen Eric M EM, Nadler Michelle B MB, Langelier David M DM, Campbell Kristin L KL et al.

Chemotherapy-induced peripheral neuropathy (CIPN) affects two-thirds of patients who receive neurotoxic chemotherapy. In almost half of these patients, CIPN is persistent, with limited treatment options. Exercise-based rehabilitation shows promising results in improving CIPN-related outcomes, but high-quality research is needed with CIPN symptoms and disability as primary endpoints. We conducted a phase I single-arm, multi-method pilot study of a 10-week remotely delivered exercise-based rehabilitation program (EX-CIPN) for adult (≥18-years) cancer survivors experiencing CIPN symptoms ≥6 months post-chemotherapy. Primary outcomes were feasibility (accrual, retention, and adherence), acceptability (interviews and surveys), and safety (CTCAE v5). Secondary outcomes included pain, CIPN symptoms, CIPN-related disability, and physiologic assessments. Assessments were conducted at baseline (T1), post-program (T2), and 3 months post-program (T3). Post-program feedback surveys were completed at T2 and semi-structured qualitative video interviews were completed between T2 and T3. In total, 36 participants (median age: 59, 83% female) consented to participate in the study. T1 retention rate (90%), adherence rates (77-96%), and no reported serious adverse events (Grade 3 CTCAE v5) supported study feasibility and safety. Interviews and surveys supported intervention acceptability. Retention rates at T2 (68%) and T3 (63%) did not reach feasibility targets. CIPN symptoms and CIPN-related disability showed significant improvement at T3 (p < 0.001). Results suggest that EX-CIPN has encouraging feasibility outcomes and is acceptable and safe. Preliminary clinical outcome results are promising. Based on these study results, we can proceed to test this intervention, with a few modifications, in a prospective randomised trial with a CIPN-related primary outcome.

PMID 42930188
阅读全文 →
PubMedBMC cancer2026-10-26

Exploration of plasma proteomic landscapes using Olink Reveal technology to identify biomarkers for early-stage/localized gastric cancer.

Ding Shao Rui SR, Li Xiang X, Dong Xiang X, Chen Ping P

Blood-based biomarkers for the early detection of gastric cancer remain limited. We conducted a systematic analysis of pre-treatment plasma proteomics profiled using the Olink Reveal panel and developed diagnostic prediction models within a leakage-controlled, outer out-of-fold (OOF) internal validation framework based on nested cross-validation. In parallel, pathway-level activity was summarized using a predefined exploratory suppressive burden index to support biological interpretation. We analysed plasma samples from 90 participants (30 healthy controls, 30 early-stage/localized gastric cancer, 30 advanced gastric cancer) using the Olink Reveal platform. Group E comprises stage T1 and T2 tumours; consequently, this group is operationally defined as early-stage/localized gastric cancer, rather than classic early gastric cancer in the strict sense. The advanced group comprised T3/T4 disease. Differential abundance was tested with age- and sex-adjusted limma models. Predictive models were developed using nested cross-validation, with preprocessing and tuning performed within training folds and performance evaluated through outer-loop OOF predicted probabilities. The suppressive burden index used predefined Reactome terms and explicit orientation signs. Age- and sex-adjusted analyses identified several proteins differentially abundant between early gastric cancer and healthy controls. Reactome term-set analyses indicated immune-related pathway variation across disease states, although these pathway-level findings should be interpreted as exploratory. OOF internal validation showed that proteomic models improved discrimination over age/sex covariates for the main early-detection task, while the relative performance of protein-only and full models varied across resampling analyses. Calibration slopes and decision-curve results were reported from OOF predictions and interpreted as internal-validation evidence only. Plasma proteomics captures systemic immune alterations associated with early-stage/localized gastric cancer and may support minimally invasive risk modeling. Given the modest single-center cohort and absence of external validation, the diagnostic models and suppressive burden index should be considered exploratory and require independent validation before clinical use.

PMID 42928152
阅读全文 →
PubMedBMC nursing2026-10-26

Effects of nurse-led shared decision-making support based on a decision aid on decisional conflict in patients with pulmonary nodules: a randomized controlled trial.

Yuan Jingmin J, Xu Haiyan H, Sun Yan Y, Chen Mingwei M et al.

To evaluate the effect of nurse-led shared decision-making support based on a decision aid on decisional conflict among patients with pulmonary nodules, and to explore its effects on psychological distress, satisfaction with participation in decision-making, and pulmonary nodule-related knowledge. The intervention group received nurse-led shared decision-making support using a decision aid in addition to physician treatment recommendations, whereas the control group received standard care. Decisional conflict, psychological distress, satisfaction with participation in decision-making, and pulmonary nodule-related knowledge were assessed immediately after the intervention (T1), at 3 months (T2), and at 6 months (T3). Causal-steps mediation analysis was conducted to examine the mediating effects of pulmonary nodule-related knowledge and satisfaction with participation in decision-making. Generalized estimating equations were used to analyze longitudinal differences between groups. A total of 98 patients were enrolled, including 47 in the intervention group and 51 in the control group. The intervention group had a significantly lower decisional conflict score than the control group after the intervention (22.87 ± 17.49 vs. 48.02 ± 19.93; t = 6.58, p < 0.001). The intervention group also had significantly higher scores for satisfaction with participation in decision-making and pulmonary nodule-related knowledge than the control group (both p < 0.001). Mediation analysis showed that shared decision-making support significantly reduced decisional conflict (B = -25.05, 95% CI -32.74 to -17.36), and this effect was mediated by improvements in pulmonary nodule-related knowledge and satisfaction with participation in decision-making. Longitudinal analysis showed that psychological distress decreased more rapidly in the intervention group during follow-up, with significant between-group differences at T1 and T2 (p < 0.001). Nurse-led shared decision-making support based on a decision aid reduced decisional conflict among patients with pulmonary nodules when integrated into routine clinical care. This effect was mainly mediated by improvements in pulmonary nodule-related knowledge and satisfaction with participation in decision-making. The intervention also showed beneficial effects in reducing psychological distress during follow-up. The study was registered in the Chinese Clinical Trial Registry on March 20, 2023(ChiCTR2300069553, retrospectively registered).

PMID 42928171
阅读全文 →
PubMedAnemia2026-10-25

Iron Status During Early and Late Pregnancy in a Swedish Multiethnic Population.

Karlsson Therese T, Forsby Mathilda M, Hagman Anna A, Jerhamre-Sundh Karin K et al.

While ethnic differences in maternal iron deficiency (ID) have been documented in other high-resource settings, such differences in Sweden remain unknown. This study assessed iron status and the prevalence of ID and anemia in pregnant women from different countries of birth in Sweden. This secondary analysis included women enrolled in the randomized controlled Pregnancy and Vitamin D Intervention study (2020-2024;). Blood samples were collected in Trimesters 1 (T1) and 3 (T3), and additional data were obtained from questionnaires and medical records. Women were categorized by region of birth: Europe, Asia, and Africa. Anemia was defined as hemoglobin (Hb) < 110 g/L, and ID was defined using two serum ferritin (SF) thresholds: < 15 and < 30 μg/L. A total of 128 women (median age 29.8 years) were included in TI, and 89 had blood samples at both T1 and T3. In those with data in both T1 and T3 (n = 89), median SF, serum iron, and Hb were significantly lower in T3 compared with T1 (all p < 0.001). Between T1 and T3, the prevalence of ID increased from 15% to 39% using SF < 15 μg/L and from 53% to 83% using SF < 30 μg/L (both p < 0.001). Anemia prevalence increased from 6% in T1 to 23% in T3 (p < 0.001). In T1, women (n = 128) from Asia and Africa more often had transferrin receptor concentrations > 4.4 mg/L than women from Europe (p = 0.02) but tended only to have a higher prevalence of SF < 15 μg/L (14% and 18% vs. 4%, p = 0.06). Self-reported use of iron supplementation (n = 89) increased from early to late pregnancy. According to medical records, 16% of women had been prescribed iron supplements during gestational weeks 6-12 and 85% by Week 32. ID was common and increased throughout pregnancy in this population in a high-resource country. No statistically significant differences were observed by region of birth. Despite prescribed iron supplements, nearly one-quarter were anemic in late pregnancy. This may reflect timing of treatment initiation, adherence, supplement dose, iron absorption, or other unknown contributors, highlighting the need to optimize iron status management during pregnancy. Trial Registration: ClinicalTrials.gov identifier: NCT05329428.

PMID 42920799
阅读全文 →
PubMedFrontiers in endocrinology2026-10-25

Cross-scale genetic, molecular, and cellular triangulation prioritizes ACSL5 as a T3-responsive candidate linking hypothyroidism liability to anemia.

Li Hui H, Jiang Tao T, Wang Huan H, Wang Mei M et al.

Anemia is a recognized complication of hypothyroidism, but disease-level genetic studies have not identified a clear erythroid cell-intrinsic target. We integrated genetic validation, molecular-QTL prioritization, and replicated triiodothyronine (T3)-responsive erythroid experiments to identify candidates linking hypothyroidism liability to anemia. Two-sample Mendelian randomization (MR) assessed genetically predicted hypothyroidism and anemia. Source metadata were reviewed for possible sample overlap, and two cross-biobank forward validations were performed. Strict reverse MR used the original OpenGWAS identifiers; because anemia provided no genome-wide-significant instruments, a post hoc analysis used p < 5 × 10-6. Non-major histocompatibility complex (MHC) methylation summary-based Mendelian randomization (SMR) and whole-blood expression SMR were integrated, followed by a public fine-mapping/colocalization lookup for two acyl-CoA synthetase long-chain family member 5 (ACSL5) cytosine-phosphate-guanine (CpG) sites and the ACSL5 eQTL. ACSL5 was examined in three independent hemin-induced K562, a human chronic myelogenous leukemia cell line experiments with or without T3; Triacsin C and oleic acid-bovine serum albumin (BSA) served as pathway-level perturbations. Primary inverse-variance weighted (IVW) analysis associated hypothyroidism liability with higher anemia odds (OR = 1.0304; 95% CI, 1.0195-1.0414; p = 3.42 × 10-8). Both primary genome-wide association studies (GWASs) were UK Biobank-derived, and their exact participant overlap could not be determined from public summary-level information. A participant-independent FinnGen hypothyroidism-to-UK Biobank anemia validation reproduced the positive direction (28 instruments; IVW beta = 0.001448, p = 4.14 × 10-4); the complementary UK Biobank hypothyroidism-to-FinnGen anemia analysis was also positive. Strict original-ID reverse MR was not estimable; the exploratory eight-instrument analysis was null and heterogeneous. Six non-MHC CpGs passed Bonferroni correction, including two mapped to ACSL5, while whole-blood ACSL5 expression showed an inverse SMR estimate. The public lookup returned no pairwise CpG-expression colocalization. In all three K562 experiments, hemin plus T3 increased HBA1, HBA2, GYPA, and ACSL5 expression. Triacsin C suppressed erythroid-marker expression, whereas oleic acid-BSA produced a partial increase without exogenous T3. Cross-scale evidence prioritizes ACSL5 as a T3-responsive candidate linking hypothyroidism liability to anemia and implicates long-chain fatty-acid handling as a research direction. However, negative CpG-expression colocalization and nongene-specific pharmacological interventions preclude a mechanistic conclusion. Direct ACSL5 perturbation and primary erythroid-cell validation are required.

PMID 42922834
阅读全文 →
PubMedJournal of dental sciences2026-10-25

Effects of 850-nm light-emitting diode photobiomodulation on pain intensity and dentin sialoprotein levels during canine distalization: A randomized controlled trial.

Cao Thanh Thuy-Nhat TT, Nguyen Anh Ho-Quynh AH, Hoang Hung Trong HT, Khac Tham Dong TD et al.

Light-emitting diode-based photobiomodulation (LED PBM) potentially reduces pain and root resorption risk in orthodontics. This study evaluated 850-nm LED PBM effects on pain and dentin sialoprotein (DSP) levels during canine distalization. This single-blind, parallel-group randomized controlled trial included 16 orthodontic patients (8 per group). Participants were randomly allocated in a 1:1 ratio to either an active LED group or a sham control group. Pain intensity was assessed using a visual analog scale (VAS) at 0, 24, and 48 h following canine distalization at four consecutive monthly visits (T1-T4) and expressed as the area under the curve (AUC0-48h). DSP concentrations in gingival crevicular fluid were measured at pretreatment (T0), initiation of distalization (T1), and follow-up visits (T2, T3) using sandwich ELISA. Longitudinal changes were analyzed using linear mixed-effects models. The LED group demonstrated a significantly lower pain intensity compared with the control group, with a significant group-by-time interaction (χ2=9.46, P=0.024). Adjusted mean values of AUC0-48h were significantly reduced in the LED group at T3 and T4, with the greatest difference observed at T3 (P < 0.001). A significant group-by-time interaction was observed for DSP (χ2 = 9.75, P = 0.021), with lower DSP levels in the LED group being reported at T1, T2, and T3 compared with the control group (P < 0.05). Repeated 850-nm LED PBM was associated with reduced cumulative pain and attenuated DSP increases during canine distalization, suggesting potential benefits for patient comfort and root resorption-related responses.

PMID 42923675
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多ior-t3